Pan-TRK immunohistochemistry in gynaecological mesenchymal tumours: diagnostic implications and pitfalls.
NTRK
fibrosarcoma
immunohistochemistry
pan-TRK
sarcoma
uterine neoplasm
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
21 Nov 2023
21 Nov 2023
Historique:
revised:
22
09
2023
received:
30
06
2023
accepted:
14
10
2023
medline:
21
11
2023
pubmed:
21
11
2023
entrez:
21
11
2023
Statut:
aheadofprint
Résumé
NTRK-rearranged sarcomas of the female genital tract mainly occur in the uterus (more commonly cervix than corpus) and are characterized by a "fibrosarcoma-like" morphology and NTRK gene rearrangements. These neoplasms may exhibit histological overlap with other entities and can present diagnostic difficulties without molecular confirmation. Pan-TRK immunohistochemistry was developed to identify tumours harbouring NTRK rearrangements. The aim of this study was to characterize pan-TRK immunohistochemical expression in a large cohort of gynaecological mesenchymal neoplasms and investigate the utility of pan-TRK immunohistochemistry to distinguish NTRK-rearranged sarcoma from its mimics. A total of 473 gynaecological mesenchymal tumours (461 without known NTRK fusions and 12 NTRK-rearranged sarcomas) were selected. Pan-TRK immunohistochemistry (EPR17341, Abcam) was performed on whole tissue sections and tissue microarrays. Molecular interrogation of pan-TRK positive tumours was performed by RNA sequencing or fluorescence in situ hybridization (FISH). Of the 12 NTRK-rearranged sarcomas, 11 (92%) exhibited diffuse (≥70%) cytoplasmic pan-TRK staining with moderate/marked intensity, while the other was negative. Eleven (2.4%) additional tumours also exhibited pan-TRK immunohistochemical expression: three low-grade endometrial stromal sarcomas, seven high-grade endometrial stromal sarcomas, and an undifferentiated uterine sarcoma. Molecular confirmation of the absence of NTRK rearrangements was possible in nine of these tumours. Of these nine neoplasms, seven exhibited focal/multifocal (<70%) pan-TRK cytoplasmic staining with weak/moderate intensity. Even though pan-TRK immunohistochemical expression is not entirely sensitive or specific for NTRK-rearranged sarcomas, these neoplasms tend to exhibit diffuse staining of moderate/strong intensity, unlike its mimics. Pan-TRK should be performed in monomorphic uterine (corpus and cervix) spindle cell neoplasms that are negative for smooth muscle markers and hormone receptors and positive for CD34 and/ or S100. Ultimately, the diagnosis requires molecular confirmation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Siozopoulou V, Smits E, de Winne K, Marcq E, Pauwels P. NTRK fusions in sarcomas: diagnostic challenges and clinical aspects. Diagnostics 2021; 11; 478.
Hechtman JF. NTRK insights: best practices for pathologists. Mod. Pathol. 2022; 35; 298-305.
Marchiò C, Scaltriti M, Ladanyi M et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann. Oncol. 2019; 30; 1417-1427.
Hung YP, Jo VY, Hornick JL. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma. Histopathology 2019; 75; 54-62.
Kao Y-C, Sung YS, Argani P et al. NTRK3 overexpression in undifferentiated sarcomas with YWHAE and BCOR genetic alterations. Mod. Pathol. 2020; 33; 1341-1349.
Chiang S, Cotzia P, Hyman DM et al. NTRK fusions define a novel uterine sarcoma subtype with features of fibrosarcoma. Am. J. Surg. Pathol. 2018; 42; 791-798.
Mills AM, Karamchandani JR, Vogel H, Longacre TA. Endocervical fibroblastic malignant peripheral nerve sheath tumor (neurofibrosarcoma): report of a novel entity possibly related to endocervical CD34 fibrocytes. Am. J. Surg. Pathol. 2011; 35; 404-412.
Costigan DC, Nucci MR, Dickson BC et al. NTRK-rearranged uterine sarcomas: clinicopathologic features of 15 cases, literature review, and risk stratification. Am. J. Surg. Pathol. 2022; 46; 1415-1429.
Chiang S. S100 and Pan-Trk staining to report NTRK fusion-positive uterine sarcoma: proceedings of the ISGyP Companion Society Session at the 2020 USCAP annual meeting. Int. J. Gynecol. Pathol. 2021; 40; 24-27.
Croce S, Hostein I, McCluggage WG. NTRK and other recently described kinase fusion positive uterine sarcomas: a review of a group of rare neoplasms. Genes Chromosomes Cancer 2021; 60; 147-159.
Solomon JP, Linkov I, Rosado A et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod. Pathol. 2020; 33; 38-46.
Hondelink LM, Schrader AMR, Asri Aghmuni G et al. The sensitivity of pan-TRK immunohistochemistry in solid tumours: a meta-analysis. Eur. J. Cancer 2022; 173; 229-237.
Gatalica Z, Xiu J, Swensen J, Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod. Pathol. 2019; 32; 147-153.
Momeni-Boroujeni A, Mohammad N, Wolber R et al. Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma. Mod. Pathol. 2021; 34; 1008-1016.
Croce S, Hostein I, Longacre TA et al. Uterine and vaginal sarcomas resembling fibrosarcoma: a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasms. Mod. Pathol. 2019; 32; 1008-1022.
Tauziède-Espariat A, Duchesne M, Baud J et al. NTRK-rearranged spindle cell neoplasms are ubiquitous tumours of myofibroblastic lineage with a distinct methylation class. Histopathology 2023; 82; 596-607.
Rabban JT, Devine WP, Sangoi AR et al. NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma. Histopathology 2020; 77; 100-111.
Devereaux KA, Weiel JJ, Mills AM, Kunder CA, Longacre TA. Neurofibrosarcoma revisited: an institutional case series of uterine sarcomas harboring kinase-related fusions with report of a novel FGFR1-TACC1 fusion. Am. J. Surg. Pathol. 2021; 45; 638-652.
Rudzinski ER, Lockwood CM, Stohr BA et al. Pan-Trk immunohistochemistry identifies NTRK rearrangements in pediatric mesenchymal tumors. Am. J. Surg. Pathol. 2018; 42; 927-935.
Bang H, Lee MS, Sung M et al. NTRK fusions in 1113 solid tumors in a single institution. Diagnostics (Basel) 2022; 12; 1450.
Parra-Herran C, Howitt BE. Uterine mesenchymal tumors: update on classification, staging, and molecular features. Surg. Pathol. Clin. 2019; 12; 363-396.
Croce S, Perret R, Le Loarer F. Update on mesenchymal lesions of the lower female genital tract. Surg. Pathol. Clin. 2022; 15; 341-367.
Haberecker M, Töpfer A, Melega F, Moch H, Pauli C. A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types. Histopathology 2023; 82; 1003-1012.
De Winne K, Sorber L, Lambin S et al. Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial. Virchows Arch. 2021; 478; 283-291.
Adam J, Stang NL, Uguen A et al. Multicenter harmonization study of pan-Trk immunohistochemistry for the detection of NTRK3 fusions. Mod. Pathol. 2023; 36; 100192.